V
39.00
-0.87 (-2.18%)
| Penutupan Terdahulu | 39.87 |
| Buka | 39.35 |
| Jumlah Dagangan | 1,603,944 |
| Purata Dagangan (3B) | 1,030,885 |
| Modal Pasaran | 3,191,416,832 |
| Harga / Jualan (P/S) | 671.45 |
| Harga / Buku (P/B) | 29.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2024 |
| Margin Operasi (TTM) | -694.43% |
| EPS Cair (TTM) | -2.00 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 93.73% |
| Nisbah Semasa (MRQ) | 13.03 |
| Aliran Tunai Operasi (OCF TTM) | -103.77 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -60.08 M |
| Pulangan Atas Aset (ROA TTM) | -28.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -78.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Verona Pharma plc | Menaik | Menaik |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.25 |
|
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.85% |
| % Dimiliki oleh Institusi | 88.91% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 74.00 (Wells Fargo, 89.74%) | Beli |
| Median | 57.00 (46.15%) | |
| Rendah | 42.00 (HC Wainwright & Co., 7.69%) | Beli |
| Purata | 57.00 (46.15%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 42.88 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Roth MKM | 10 Jan 2025 | 68.00 (74.36%) | Beli | 45.20 |
| Truist Securities | 08 Jan 2025 | 57.00 (46.15%) | Beli | 46.20 |
| Wells Fargo | 08 Jan 2025 | 74.00 (89.74%) | Beli | 46.20 |
| 05 Nov 2024 | 64.00 (64.10%) | Beli | 38.39 | |
| Canaccord Genuity | 05 Nov 2024 | 44.00 (12.82%) | Beli | 38.39 |
| HC Wainwright & Co. | 05 Nov 2024 | 42.00 (7.69%) | Beli | 38.39 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Jan 2025 | Pengumuman | Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights |
| 19 Nov 2024 | Pengumuman | Verona Pharma Announces December 2024 Investor Conference Participation |
| 05 Nov 2024 | Pengumuman | Verona Pharma to Present at Jefferies London Healthcare Conference |
| 04 Nov 2024 | Pengumuman | Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| 21 Oct 2024 | Pengumuman | Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |